Basecamp Bio
Provider of integrated enabling capabilities for cell and gene therapies, combining gene-editing discovery and engineering with process development, cGMP manufacturing, analytical and regulatory support, and partnerships to accelerate development and manufacturing of genetic medicines.
Industries
Nr. of Employees
small (1-50)
Basecamp Bio
Headquartered in Cambridge, MA; BaseCamp located in Waltham, MA
Products
Lentiviral vector production platform (suspension-based)
A suspension-culture lentiviral vector manufacturing platform designed for scalable production from research to GMP supply, with customizable processes for partner needs.
Diverse gene editing enzyme collection and modular base editor systems
A curated collection of small, diverse RNA-guided nucleases and engineered base editors intended to expand genomic target coverage and enable allele-selective and multiplex editing.
LNP delivery research platform
An LNP research platform focused on tissue targeting and de-targeting capabilities to support in vivo nucleic acid and gene editing delivery strategies.
Internal NGS core and bioinformatics platform
Sequencing infrastructure and analysis pipelines to support genomic characterization, QC, and data-quality requirements for R&D and manufacturing.
Investigational allele-selective gene editing therapeutic (preclinical/early development)
An internal program advancing allele-selective gene editing approaches for neurological disease using targeted nuclease and base-editing strategies validated in preclinical models.
Lentiviral vector production platform (suspension-based)
A suspension-culture lentiviral vector manufacturing platform designed for scalable production from research to GMP supply, with customizable processes for partner needs.
Diverse gene editing enzyme collection and modular base editor systems
A curated collection of small, diverse RNA-guided nucleases and engineered base editors intended to expand genomic target coverage and enable allele-selective and multiplex editing.
LNP delivery research platform
An LNP research platform focused on tissue targeting and de-targeting capabilities to support in vivo nucleic acid and gene editing delivery strategies.
Internal NGS core and bioinformatics platform
Sequencing infrastructure and analysis pipelines to support genomic characterization, QC, and data-quality requirements for R&D and manufacturing.
Investigational allele-selective gene editing therapeutic (preclinical/early development)
An internal program advancing allele-selective gene editing approaches for neurological disease using targeted nuclease and base-editing strategies validated in preclinical models.
Services
On-site manufacture of clinical- and commercial-stage cell and gene therapy materials within cGMP suites, supported by automated and digital workflows for scale-up.
Process design and optimization for upstream and downstream unit operations with transfer readiness to GMP manufacturing.
Development, qualification, and validation of analytical methods and potency assays to support regulatory submissions and product release.
Sequencing, data processing, and bioinformatics to support R&D, QC, and release testing workflows.
Discovery, characterization, and engineering of novel nucleases and base editors, plus computational design and experimental optimization services for editing systems.
Regulatory strategy, CMC documentation, and quality-system support to prepare regulatory filings and maintain manufacturing compliance.
On-site manufacture of clinical- and commercial-stage cell and gene therapy materials within cGMP suites, supported by automated and digital workflows for scale-up.
Process design and optimization for upstream and downstream unit operations with transfer readiness to GMP manufacturing.
Development, qualification, and validation of analytical methods and potency assays to support regulatory submissions and product release.
Sequencing, data processing, and bioinformatics to support R&D, QC, and release testing workflows.
Discovery, characterization, and engineering of novel nucleases and base editors, plus computational design and experimental optimization services for editing systems.
Regulatory strategy, CMC documentation, and quality-system support to prepare regulatory filings and maintain manufacturing compliance.
Expertise Areas
- Gene editing and base editing
- Computational biology and AI-driven protein engineering
- High-throughput screening and robotics for protein/nuclease optimization
- cGMP manufacturing for cell and gene therapies
Key Technologies
- Next-generation sequencing (NGS)
- RNA-guided nucleases (RGNs) and CRISPR-type systems
- Base editing (adenine and cytosine deaminase-based editors)
- Lipid nanoparticle (LNP) delivery systems
News & Updates
Certification recognizing commercial cell and gene therapy manufacturing capabilities at the company's BaseCamp facility.
Raised $401 million in Series D financing to support company growth and portfolio development.
New U.S. patents covering lead gene-editing systems and adenine deaminases supporting advanced base-editing techniques.
Announcement that an allogeneic, off-the-shelf, multi-virus specific T-cell therapy company joined the company's portfolio to leverage integrated bench-to-bedside capabilities.
Award from a disease-focused foundation to explore base-editing approaches for correcting common nonsense mutations in the CFTR gene using diverse nucleases and engineered base editors.
Appointment of a strategic scientific advisor to provide immunology and cell therapy development expertise as the company expanded immunotherapy platform capabilities.
Certification recognizing commercial cell and gene therapy manufacturing capabilities at the company's BaseCamp facility.
Raised $401 million in Series D financing to support company growth and portfolio development.
New U.S. patents covering lead gene-editing systems and adenine deaminases supporting advanced base-editing techniques.
Announcement that an allogeneic, off-the-shelf, multi-virus specific T-cell therapy company joined the company's portfolio to leverage integrated bench-to-bedside capabilities.
Award from a disease-focused foundation to explore base-editing approaches for correcting common nonsense mutations in the CFTR gene using diverse nucleases and engineered base editors.
Appointment of a strategic scientific advisor to provide immunology and cell therapy development expertise as the company expanded immunotherapy platform capabilities.